<DOC>
	<DOCNO>NCT01987908</DOCNO>
	<brief_summary>Sickle cell disease ( SCD ) genetic blood disorder characterize presence sickle-shaped red blood cell . In U.S. U.K. occur primarily person African origin . There one drug ( hydroxyurea ) approve manage SCD , fully efficacious produce medically significant side effect . Aes-103 evaluate novel agent long term management SCD . By directly reduce sickling process , Aes-103 different mechanism action hydoxyurea . The active ingredient Aes-103 5-hydroxymethyl furfural , naturally occur small molecule chemically relate glucose . This study evaluate safety pharmacokinetic profile two dose regimen Aes-103 28 day 50 adult subject stable SCD compare subject receive placebo .</brief_summary>
	<brief_title>Evaluation Different Dose Regimens Aes-103 Given 28 Days Subjects With Stable Sickle Cell Disease</brief_title>
	<detailed_description>This study evaluate evaluate subject stable SCD safety , pharmacokinetic profile , clinical pharmacology action clinical activity two dose regimen Aes-103 ( 1000 mg four time daily Cohort A high low dose give daily four time daily Cohort B ) give 28 day adult subject stable SCD compare subject receive placebo .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Male female , age 1860 year old , inclusive Diagnosis SCD ( hemoglobin SS ) without hospitalization pain crisis reason 14 day enrollment Have normal organ function define direct bilirubin &lt; 1.1 mg/dL ( 19 μmol/L ) , alanine transaminase ( serum glutamic pyruvic transaminase ) ≤120 IU/L , Creatinine ≤1.3 mg/dL ( 115 μmol/L ) Have least one follow baseline value : hemoglobin level &lt; 10 g/dL , numerical pain rating scale ( NPRS ) score ≥ 4 , 6minute walk distance ( 6MWD ) &lt; 500 If female , nonpregnant nonbreastfeeding surgically sterile use acceptable method contraception throughout study 3 month last dose study medication Have complete outpatient screen visit consist medical history , physical examination , 12lead electrocardiogram ( ECG ) , vital sign , hematology chemistry test , urinalysis , urine drug screen , urine serum pregnancy test ( female ) , hemoglobin electrophoresis , hepatitis B C screening , HIV serology Be able understand provide write informed consent include signature inform consent form approve institutional review board independent ethic committee Have provide write authorization use disclosure protect health information Agree abide study schedule return require assessment Have hospitalize 14 day enrollment , reason Have evidence clinically significant cardiovascular , respiratory , renal , hepatic , pulmonary , gastrointestinal , hematological , neurological , psychiatric , disease may interfere objective study safety subject , hospitalize past 6 month result condition ( SCDrelated morbidity , minimum 14 day last hospitalization require )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pain</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>6 minute walk test</keyword>
	<keyword>5-HMF</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Analgesic use</keyword>
	<keyword>Sickle cell disease</keyword>
	<keyword>Aes-103</keyword>
	<keyword>SpO2</keyword>
	<keyword>Anemia</keyword>
	<keyword>Hemoglobin</keyword>
</DOC>